• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A biotech company developing and commercializing vaccines for infectious diseases with major unmet needs

VAL_Report_2018_Teaser_Website_Home_800x400_190320.jpg

Download 2018 Valneva Annual Business Report


March 21, 2019
Valneva Announces the Availability of its FY 2018 Audited Consolidated and Statutory Financial Statements
Read more

— Stock information

@valnevase




-
— January 31, 2019
Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate

Read more
— Vienna Stock Exchange Delisting /
Delisting von der Wiener Börse

Shareholder information
Informationen für Aktionäre


— Financial Calendar
March 21, 2019
2018 Consolidated and Statutory Financial Statements (audited)

May 2, 2019
Q1 2019 Interim Results

See all dates

AKTUELLES

News in German


 
VALNEVA
LIBRARY


Images, presentations and videos

JAPANESE
ENCEPHALITIS
AND
CHOLERA



learn more
play video Company Video

– Upcoming conferences



March 25-27, 2019
BIO-Europe Spring, Vienna, Austria

April 15-17, 2019

World Vaccine Congress, Washington D.C., US
 
Please update your browser...